Danaher Corp views artificial intelligence in drug discovery as a long-term revenue driver, CEO Julie Montgomery said on Wednesday morning. The life sciences firm is positioning its instrument portfolio to capture growing adoption among pharmaceutical developers. Drugmakers increasingly turn to machine learning to streamline research and compress development timelines.
Danaher Backs AI Drug Discovery
Danaher executives stated that the life sciences firm is well positioned to benefit from increasing industry adoption of artificial intelligence in drug development. The company cited its extensive portfolio and partnerships as key advantages in capturing emerging demand.
Xurve View
Insights:
Xurve View






